Results 21 to 30 of about 2,842 (113)

Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital

Microbiologia Medica, 2022
Background and aims: Meropenem (Mer) and vaborbactam (Vab) is a combination of a carbapenem and a new β-lactamase inhibitor used in adults to treat different types of infections caused by Gram-negative bacteria.
Giuseppina Amarù, Lara Scoppapietra, Cristina Crocillà, Marika Salafia, Mara Finotti, Vittorio Schiavo, Valentino Granero   +6 more
doaj   +1 more source

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

Antibiotics, 2021
The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients.
Ruiying Han, Dan Sun, Sihan Li, Jiaojiao Chen, Mengmeng Teng, Bo Yang, Yalin Dong, Taotao Wang   +7 more
doaj   +1 more source

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics

Frontiers in Microbiology, 2021
QPX7728 is a novel β-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates. The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere (meropenem-vaborbactam).
Olga Lomovskaya, Ruslan Tsivkovski, Dongxu Sun, Raja Reddy, Maxim Totrov, Scott Hecker, David Griffith, Jeffery Loutit, Michael Dudley   +8 more
doaj   +1 more source

Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations

Journal of Global Antimicrobial Resistance, 2023
: Objectives: Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (
A. Oliva, D. Al Ismail, G. Arcari, MC. Miele, E. Casali, F. Sacco, L. Volpicelli, M. De Angelis, M.T. Mascellino, F. Cancelli, G. Raponi, A. Carattoli, M Venditti   +12 more
doaj   +1 more source

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study

Infection and Drug Resistance, 2022
Raghdaa Shrief,1 Amira H El-Ashry,2 Rasha Mahmoud,3 Rasha El-Mahdy2 1Medical Microbiology and Immunology Department, Faculty of Medicine, Damietta University, Damietta, Egypt; 2Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura
Shrief R, El-Ashry AH, Mahmoud R, El-Mahdy R   +3 more
doaj  

Correlation between Mechanism of Carbapenem Resistance and in vitro Efficacy of Ceftazidime-Avibactam and Meropenem-Vaborbactam on Carbapenem-Resistant Enterobacterales and Pseudomonas Aeruginosa

Pakistan Armed Forces Medical Journal, 2022
Objective: To determine the mechanism of Carbapenem resistance, type of Carbapenemase produced and in vitro efficacy of Ceftazidime-Avibactam (CAZ-AVI) and Meropenem-Vaborbactam (MEV) against Carbapenem-resistant Enterobacterales and in vitro efficacy ...
Fatima Ali, Irfan Ali Mirza, Hafsa Waseem, Umer Khursheed, Humaira Zafar, Maryiam Sarwar   +5 more
doaj   +1 more source

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

Transplant Infectious Disease, EarlyView.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea   +6 more
wiley   +1 more source

Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin

Journal of Global Antimicrobial Resistance
Objective: A case of post-neurosurgical ventriculitis caused by a KPC-producing Klebsiella pneumoniae (KPC-Kp) with a ceftazidime/avibactam-resistant, meropenem-susceptible phenotype is reported.
Lorenzo Volpicelli, Sara Cairoli, Dania Al Ismail, Floriana Baisi, Federica Sacco, Bianca Maria Goffredo, Mario Venditti, Alessandra Oliva   +7 more
doaj   +1 more source

Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals

Scientific Reports, 2023
Carbapenem-resistant Klebsiella pneumoniae (CRKP) are highly disseminated worldwide, and isolates co-resistant to other antimicrobial agents pose a threat to effective antimicrobial therapy. Therefore, evaluation of novel antimicrobial drugs is needed to
Carlos Henrique Camargo, Amanda Yaeko Yamada, Andreia Rodrigues de Souza, Marcos Paulo Vieira Cunha, Pedro Smith Pereira Ferraro, Claudio Tavares Sacchi, Marlon Benedito dos Santos, Karoline Rodrigues Campos, Monique Ribeiro Tiba-Casas, Maristela Pinheiro Freire, Pasqual Barretti   +10 more
doaj   +1 more source

Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug‐Resistant Pseudomonas aeruginosa Pneumonia: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zuoren Zhou, Jinqi Zhu, Ge Wu, Xi Kang, Qing Wang, Jie Liu, Yan Jiang   +6 more
wiley   +1 more source